Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Eterna Therapeutics ( (ERNA) ).
On May 1, 2026, Ernexa Therapeutics Inc. filed a certificate of amendment in Delaware to implement a 1-for-25 reverse stock split of its common stock, consolidating existing shares into fewer, higher-priced shares. Effective at the market open on May 4, 2026, the company’s common stock began trading on a split-adjusted basis on Nasdaq under a new CUSIP, a move that is typically aimed at maintaining listing compliance and could affect trading dynamics and shareholder ownership structure.
The reverse split does not change the company’s overall market capitalization directly, but it reduces the number of shares outstanding, which can increase the per-share price and potentially broaden institutional investor interest. For existing shareholders, the transaction alters the number of shares they hold while preserving their proportional ownership, signaling management’s focus on capital markets positioning and continued access to Nasdaq.
More about Eterna Therapeutics
Ernexa Therapeutics Inc. is a publicly traded biotechnology company whose common stock is listed on the Nasdaq market, giving it access to public equity investors and subjecting it to U.S. securities listing standards and corporate governance requirements.
Average Trading Volume: 1,856,342
Technical Sentiment Signal: Strong Sell
Current Market Cap: $4.45M
See more insights into ERNA stock on TipRanks’ Stock Analysis page.